医疗补助政策与酒精相关性肝病肝移植
该研究调查美国各州医疗补助政策对酒精相关性肝病(ALD)肝移植的影响,比较限制性(要求戒酒记录/康复)与非限制性政策。2002-2017年10836例ALD肝移植受者中,2012-2017年限制性州医疗补助支付比例显著低于非限制性州(17.2% vs 23.2%,P=0.005),双重差分显示限制性政策与2011年后医疗补助支付肝移植比例绝对降低4.7%相关。
要点
- 限制性医疗补助政策要求戒酒记录或康复,与非限制性政策相比,2011年后ALD肝移植中医疗补助支付比例更低。
- 2012-2017年限制性州医疗补助支付比例为17.2%,非限制性州为23.2%(P=0.005)。
- 双重差分分析显示限制性政策与2011年后医疗补助支付比例绝对降低4.7%(0.8%-8.6%)相关(P=0.02)。
核心结论
- 限制性医疗补助政策与2011年后ALD肝移植中医疗补助支付比例较低相关。
- 建议重新评估医疗补助酒精使用政策以更贴合当代中心实践。
研究设计与样本
- 调查所有活跃肝移植中心的州医疗补助政策,并链接2002-2017年全国登记数据。
- 纳入10836例以ALD为主要 listing 诊断的肝移植受者,限制性州7091例,非限制性州3745例。
- 采用双重差分分析比较2002-2011年与2012-2017年,并进行敏感性分析。
主要发现
- 2002-2011年限制性州与非限制性州医疗补助支付调整比例分别为17.6%(15.4%-19.8%)与18.9%(15.4%-22.3%)(P=0.54)。
- 2012-2017年限制性州与非限制性州医疗补助支付调整比例分别为17.2%(14.7%-19.7%)与23.2%(19.8%-26.6%)(P=0.005)。
- 双重差分分析中,限制性政策与2011年后医疗补助支付比例绝对降低4.7%(0.8%-8.6%)相关(P=0.02)。
临床怎么用
- 临床医生应了解所在州医疗补助政策对ALD肝移植覆盖的限制,可能影响患者移植可及性。
- 政策制定者可考虑重新评估限制性酒精使用政策,以与中心早期移植实践对齐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: In some states, liver transplantation (LT) for alcohol-associated liver disease (ALD) is covered by Medicaid only with documentation of abstinence and/or alcohol rehabilitation. Different Medicaid policies may affect the distribution of LT for ALD, particularly post-2011, as centers have adopted early (i.e., specific abstinence period not required) LT practices. APPROACH AND RESULTS: We surveyed Medicaid policies in all states actively performing LT and linked state policies to prospectively collected national registry data on LT recipients from 2002 to 2017 with ALD as the primary listing diagnosis. We categorized Medicaid policies for states as "restrictive" (requiring documentation of a specific abstinence period and/or rehabilitation) versus "unrestrictive" (deferring to center eligibility policies). Difference-of-differences analysis, comparing 2002-2011 versus 2012-2017, evaluated whether restrictive policies were associated with decreased proportion of LTs paid by Medicaid among patients with ALD post-2011. We performed sensitivity analyses to account for any differences by diagnosis of hepatocellular carcinoma, hepatitis C virus, nonalcoholic steatohepatitis, or Medicare insurance. We also performed a sensitivity analysis to account for any difference by prevalence of ALD among restrictive versus unrestrictive states. Of 10,836 LT recipients in 2002-2017, 7,091 were from 24 states in the restrictive group and 3,745 from 14 states in the unrestrictive group. The adjusted proportion (95% confidence interval) of LTs paid by Medicaid among restrictive versus unrestrictive states between 2002 and 2011 was 17.6% (15.4%-19.8%) versus 18.9% (15.4%-22.3%) (P = 0.54) and between 2012 and 2017, 17.2% (14.7%-19.7%) versus 23.2% (19.8%-26.6%) (P = 0.005). In difference-of-differences analysis, restrictive (versus unrestrictive) policies were associated with a 4.7% (0.8%-8.6%) (P = 0.02) absolute lower adjusted proportion of LTs for ALD paid by Medicaid post-2011. CONCLUSIONS: Restrictive Medicaid policies are present in most states with active LT centers and are associated with lower proportions of LTs for ALD paid by Medicaid post-2011 compared to states with unrestrictive Medicaid policies. Reevaluation of Medicaid alcohol use policies may be warranted, to align more closely with contemporary center-level practices.
引用
- Lee BP, Vittinghoff E, Pletcher MJ, et al. Medicaid Policy and Liver Transplant for Alcohol-Associated Liver Disease. Hepatology. 2020. PMID: 31705545. doi:10.1002/hep.31027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。